ANALYSIS: With an Obermatt 360° View of 42 (better than 42% compared with alternatives), overall professional sentiment and financial characteristics for the stock Esperion Therapeutics are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Esperion Therapeutics. The consolidated Value Rank has an attractive rank of 69, which means that the share price of Esperion Therapeutics is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 69% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 78, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 28. Professional investors are more confident in 72% other stocks. Worryingly, the company has risky financing, with a Safety rank of 13. This means 87% of comparable companies have a safer financing structure than Esperion Therapeutics. ...read more